Connect to other sites within the UBM Medica Network
Adding Palifosfamide Fails to Improve Survival in Metastatic Sarcoma
The addition of palifosfamide to doxorubicin failed to improve survival in a phase III trial of patients with metastatic soft-tissue sarcoma.
Better Imaging Method for Ewing Sarcoma Response Assessment
Functional imaging using FDG-positron emission tomography (FDG-PET) was able to predict response to treatment in Ewing sarcoma patients, and was superior to other anatomic imaging criteria.
Alisertib Shows Promise in Soft-Tissue Sarcoma
Alisertib yielded promising progression-free survival in advanced/metastatic soft-tissue sarcoma patients, though it did not meet its primary response rate endpoint.
Genomic Analysis Finds Large Burden of Genetic Risk in Sarcoma Patients
A comprehensive genomic analysis of more than a thousand sarcoma patients found that about half had putatively pathogenic variations in either known or novel cancer genes.
Patient With Abdominal Inflammatory Myofibroblastic Tumor
A 37-year-old Lebanese male with no significant past medical history initially presented with an increase in abdominal girth over a few weeks with worsening shortness of breath, nausea, and intermittent vomiting.
Fusion-Negative Sarcoma Survivors Have Increased Risk of Second Malignancies
Survivors of fusion-negative sarcomas have a higher risk of developing a second malignant neoplasm than those who had fusion-positive sarcomas.
Selinexor Shows Promise in Phase I Sarcoma Trial
A phase I trial of selinexor found the drug was reasonably well tolerated and showed some activity in patients with advanced soft-tissue or bone sarcoma with progressive disease.
Drug Shows 10-Month Survival Improvement in Sarcoma
In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.
Slide Show: Gastrointestinal Stromal Tumors
This slide show features a CT image, and pathology images of gastrointestinal stromal tumors (GISTs) arising in the stomach using H&E, CD34, and c-Kit staining.
By clicking Accept, you agree to become a member of the UBM Medica Community.